Clinical Trial Update: CT Antigen TCR-Engineered T Cells for Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates for CT antigen TCR-engineered T cells in multiple myeloma; the study is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CT antigen TCR-engineered T cells

Snippet

Sponsor: Adaptimmune | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-07-24